BTK and B-cell chronic lymphocytic leukemia: Ibrutinib is a small molecule that binds covalently to Cys-481 in the ATP binding of the kinase domain of Bruton Tyrosine Kinase (BTK), which is overexpressed and constitutively active in B cell malignancies, including CLL [8].